David A. Siegel Nurix Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 195,400 shares of NRIX stock, worth $2.44 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

195,400

Previous 79,100 147.03%

Holding current value

$2.44 Million

Previous $1.49 Million 55.77%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$11.88 - $20.15 $1.38 Million - $2.34 Million	116,300 Added 147.03%	195,400 $2.32 Million
Q4 2024 Feb 14, 2025	BUY	$18.64 - $28.14 $372,800 - $562,800	20,000 Added 33.84%	79,100 $1.49 Million
Q3 2024 Nov 14, 2024	SELL	$18.93 - $25.69 $575,472 - $780,976	-30,400 Reduced 33.97%	59,100 $1.33 Million
Q2 2024 Aug 14, 2024	SELL	$12.02 - $21.3 $1.06 Million - $1.88 Million	-88,400 Reduced 49.69%	89,500 $1.87 Million
Q1 2024 May 15, 2024	BUY	$7.77 - $15.66 $1.16 Million - $2.33 Million	148,800 Added 511.34%	177,900 $2.62 Million
Q4 2023 Feb 14, 2024	BUY	$4.25 - $10.71 $42,075 - $106,029	9,900 Added 51.56%	29,100 $300,000
Q3 2023 Nov 14, 2023	BUY	$7.86 - $10.08 $31,440 - $40,320	4,000 Added 26.32%	19,200 $150,000
Q2 2023 Aug 14, 2023	BUY	$8.7 - $13.28 $28,709 - $43,824	3,300 Added 27.73%	15,200 $151,000
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $101,864 - $157,794	11,900 New	11,900 $105,000
Q2 2022 Aug 15, 2022	SELL	$7.88 - $14.82 $96,136 - $180,804	-12,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $157,868 - $361,730	12,200 New	12,200 $171,000

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

74.4M

Call Options Held

56.9K

Put Options Held

7.9K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $589M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account